Melanoma-associated antigen 4 (MAGE-A4)
MAGE-A4 is a cancer-testis antigen expressed in select tumors. Expression is required for eligibility for certain engineered T-cell therapies.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where Melanoma-associated antigen 4 (MAGE-A4) is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Synovial sarcoma Solid Tumor · Soft Tissue |
|
Approvals defined at the solid tumor level where Melanoma-associated antigen 4 (MAGE-A4) is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report Melanoma-associated antigen 4 (MAGE-A4) as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports Melanoma-associated antigen 4 (MAGE-A4) as part of its biomarker panel.